Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Launched by MEDICAL UNIVERSITY OF LUBLIN · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between a protein called sclerostin and bone problems in patients with a condition known as mastocytosis. Mastocytosis is a rare disease where certain cells called mast cells build up in the body, and these can sometimes cause issues in the bones. The researchers want to understand how sclerostin might be involved in the bone issues that some patients with mastocytosis experience.

To participate in this trial, you need to be over 18 years old and have a confirmed diagnosis of mastocytosis based on specific medical criteria. You also need to know your KIT mutation status, which is a genetic factor related to this disease. While the trial is open to all genders, some people may not be eligible, such as those who have had an organ transplant, are pregnant or breastfeeding, or have other serious health issues. Participants will help researchers learn more about how sclerostin affects bone health in mastocytosis, which could lead to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • Mastocytosis defined according to WHO criteria
• • Known KIT mutation status
• Exclusion Criteria:
• • History of organ transplant
• • Inability to give informed consent
• • Pregnancy, Breastfeeding
• • Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection

Trial Officials